1 Top Wall Street Analyst Thinks CRISPR Therapeutics Could More Than Double. Should You Buy the Stock Hand Over Fist?

CRISPR Therapeutics has bullish analyst sentiment with Piper Sandler's Edward Tenthoff setting a $110 price target, implying over 100% upside. The biotech's prospects are supported by upcoming clinical trial data for CTX611 (an anticoagulant targeting a $20B market), expansion of its approved Casgevy gene therapy to children, and a deep pipeline. However, the stock remains risky due to dependence on positive clinical results and execution.